Fortune India 500 2025 edition
Rank#352- Total income
- ₹7,018 Cr
- Profit
- ₹583 Cr
Last year #348
Alembic Pharmaceuticals Limited - pharma in Vadodara, Gujarat, India. FY 2026 financials & compliance.
Active Listed - NSE: APLLTD · BSE: 533573 Public Limited Company pharma Fortune India 500 · #352 BSE 500
Market Cap
₹15,357 Cr
APLLTD · NSE
Share Price
₹760.10
-2.71% today
Revenue
₹7,345 Cr
FY 2025-26 · +10.1% YoY
EBITDA
₹1,051 Cr
Margin 14.3%
Net Profit
₹731 Cr
FY 2025-26 · +29.8% YoY
P/E (TTM)
20.8x
P/B 2.7x
ROE
12.3%
ROCE 11.2%
Debt / Equity
0.25
Interest cover 12.8x
About Alembic Pharmaceuticals Limited
Data last updated:
Alembic Pharmaceuticals Limited is a public limited company based in Vadodara, Gujarat, India, a subsidiary of Nirayu Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 16 June 2010 and has been in existence for over 16 years.
Alembic Pharmaceuticals is ranked #352 on the Fortune India 500 (2025). It is part of the BSE 500 index. Its director Sujit Jaysukh Bhayani and family are #326 among India's richest people (2026). Its director Chirayu R Amin and family are #338 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ2010PLC061123. Its GSTIN is 24AAICA5591M1Z9 (Gujarat). The company holds 28 GST registrations, of which 23 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 533573 and NSE: APLLTD.
The company has an authorised share capital of ₹40.5 Cr and a paid-up capital of ₹39.31 Cr. It was formerly known as Alembic Pharma Limited. It is led by directors including Pranav Chirayu Amin (Managing Director) and Shaunak Chirayu Amin (Managing Director).
Its last annual general meeting (AGM) was held on 05 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Alembic Road, Vadodara, Gujarat, India – 390003.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹7,344.9 Cr, a growth of 10.1% compared to the previous year. For the same year it recorded a net profit of ₹730.89 Cr (net margin 10%) and EBITDA of ₹1,051.47 Cr (EBITDA margin 14.3%). The net worth stands at ₹5,674.81 Cr (up 9.3% YoY). Total assets are valued at ₹7,432.01 Cr (up 13.1% YoY).
The company has about 15,822 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Alembic Pharmaceuticals and Alembic Limited. As per MCA filings, the company has open charges of ₹600 Cr and satisfied charges of ₹219.36 Cr on record. Court records list 358 cases involving the company, including 305 filed by the company and 53 filed against it; 97 cases are pending. The company has 10 deals on record (8 market trades, 1 qip, 1 acquisition); the latest was in October 2022. Its 9 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Emcure Pharmaceuticals Limited with revenue of ₹7,963.26 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website alembicpharmaceuticals.com.
Company details
CIN L24230GJ2010PLC061123
Registration Number 061123
Incorporation Date 16 June 2010
ROC Ahmedabad
Listing Status Listed - Listed on NSE (APLLTD); Listed on BSE (533573)
Company Status Active
Date of Last AGM 05 August 2025
Date of Balance Sheet 31 March 2026
Parent Company Nirayu Limited
Compliance Status Active Compliant
CIN history
Alembic Pharmaceuticals has one previous CIN (Corporate Identification Number): U24230GJ2010PLC061123. The current CIN is L24230GJ2010PLC061123, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230GJ2010PLC061123 | Current |
| U24230GJ2010PLC061123 | Previous |
Key People
Pranav Chirayu Amin Managing Director Shaunak Chirayu Amin Managing Director Chirayu Ramanbhai Amin Whole-Time Director Recognitions & Rankings of Alembic Pharmaceuticals
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#261- Valuation
- ₹21,690 Cr
2023 #272 2022 #312 2021 #243
India's Richest People 2026 edition · 3 directors · Source: Hurun India
- #326 Sujit Jaysukh Bhayani & family ₹11,600 Cr
- #338 Chirayu R Amin & family ₹11,100 Cr
- #724 Manish Kejriwal & family ₹4,400 Cr
Stock market indices
BSE 500
Contact details
Alembic Pharmaceuticals Limited's registered office is in Vadodara, Gujarat. Its website is alembicpharmaceuticals.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressAlembic Road, Vadodara, Gujarat, India – 390003
- IndustryPharma, API Manufacturers
To see the full contact details of Alembic Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Alembic Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Alembic Pharmaceuticals operates two associated brands: Alembic Pharmaceuticals and Alembic Limited. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer & supplier of generic pharmaceuticals | alembicpharmaceuticals.com | |
| Active pharmaceutical ingredients are manufactured by Alembic. | alembiclimited.com |
Business activity
The main business activity of Alembic Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Alembic Pharmaceuticals Limited, buy the company report.
Financials of Alembic Pharmaceuticals Limited
FY 2025-26 filings availableAlembic Pharmaceuticals Limited reported revenue of ₹7,344.9 Cr (up 10.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹7,345 Cr
+10.1% YoY
EBITDA
₹1,051 Cr
+4.3% YoY
Profit After Tax
₹731 Cr
+29.8% YoY
Net Worth
₹5,675 Cr
+9.3% YoY
Total Assets
₹7,432 Cr
+13.1% YoY
Total Debt
₹1,430 Cr
+13.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 7,345 | 6,672 | 6,229 | 5,653 | 5,306 | 5,393 | 4,606 |
| Revenue growth | +10.1% | +7.1% | +10.2% | +6.5% | -1.6% | +17.1% | - |
| EBITDA | 1,051 | 1,008 | 932 | 677 | 874 | 1,480 | 1,179 |
| EBITDA margin | +14.3% | +15.1% | +15.0% | +12.0% | +16.5% | +27.5% | +25.6% |
| Profit before tax | 694 | 707 | 632 | 355 | 625 | 1,368 | 1,000 |
| Net profit | 731 | 563 | 613 | 346 | 518 | 1,141 | 862 |
| Net profit margin | +10.0% | +8.4% | +9.8% | +6.1% | +9.8% | +21.2% | +18.7% |
| EPS (₹) | 34.33 | 29.68 | 31.33 | 17.40 | 26.50 | 58.33 | 43.97 |
| Balance sheet | |||||||
| Total assets | 7,432 | 6,571 | 5,441 | 5,199 | 6,050 | 5,736 | 5,086 |
| Net worth | 5,675 | 5,191 | 4,818 | 4,370 | 5,238 | 5,067 | 3,219 |
| Total debt | 1,430 | 1,258 | 513 | 722 | 717 | 584 | 1,747 |
| Cash & bank | 203 | 90.10 | 127 | 82.27 | 69.43 | 106 | 80.75 |
| Net working capital | 3,212 | 2,886 | 2,074 | 1,926 | 1,789 | 1,496 | 1,572 |
| Cash flow | |||||||
| Cash from operations | 783 | 87.96 | 803 | 724 | 552 | 1,463 | 449 |
| Cash from investing | (506) | (568) | (321) | (448) | (372) | (840) | (731) |
| Cash from financing | (164) | 444 | (438) | (262) | (217) | (597) | 155 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,150 | 1,848 | 1,876 | 1,910 | 1,711 | 1,770 | 1,693 | 1,648 |
| Revenue growth (YoY) | +25.7% | +4.4% | +10.8% | +15.9% | +9.5% | - | - | - |
| Other income | 15.32 | 26.61 | 15.50 | 8.33 | 6.50 | 14.19 | 9.86 | 30.47 |
| EBITDA | 332 | 203 | 249 | 316 | 281 | 271 | 260 | 239 |
| EBITDA margin | +15.4% | +11.0% | +13.3% | +16.5% | +16.4% | +15.3% | +15.4% | +14.5% |
| Depreciation | 97.71 | 88.59 | 80.12 | 76.07 | 73.77 | 68.99 | 70.04 | 70.51 |
| Interest | 27.61 | 22.56 | 23.31 | 24.23 | 23.52 | 24.52 | 22.26 | 18.81 |
| Profit before tax | 222 | 119 | 162 | 224 | 190 | 192 | 178 | 180 |
| Tax | 49.50 | (82.91) | 29.55 | 40.01 | 36.48 | 35.31 | 40.08 | 27.28 |
| Net profit | 172 | 202 | 132 | 184 | 154 | 157 | 138 | 153 |
| EPS (₹) | 8.80 | 10.31 | 6.76 | 9.40 | 7.85 | 7.98 | 7.01 | 7.79 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 6,651 | 6,033 | 5,874 | 5,149 | 5,035 | 5,067 | 4,133 |
| Revenue growth | +10.3% | +2.7% | +14.1% | +2.3% | -0.6% | +22.6% | - |
| EBITDA | 996 | 901 | 525 | 664 | 909 | 1,449 | 1,193 |
| EBITDA margin | +15.0% | +14.9% | +8.9% | +12.9% | +18.1% | +28.6% | +28.9% |
| Profit before tax | 654 | 609 | 704 | 346 | 658 | 1,338 | 1,167 |
| Net profit | 697 | 483 | 665 | 347 | 541 | 1,091 | 976 |
| Net profit margin | +10.5% | +8.0% | +11.3% | +6.7% | +10.7% | +21.5% | +23.6% |
| EPS (₹) | 32.58 | 25.60 | 33.91 | 17.64 | 27.65 | 55.79 | 51.43 |
| Balance sheet | |||||||
| Total assets | 6,966 | 6,513 | 5,510 | 5,230 | 6,092 | 5,771 | 5,180 |
| Net worth | 5,615 | 5,195 | 4,909 | 4,414 | 5,290 | 5,102 | 3,346 |
| Total debt | 1,198 | 1,194 | 492 | 710 | 706 | 584 | 1,687 |
| Cash & bank | 28.74 | 20.85 | 26.49 | 28.46 | 21.90 | 61.44 | 37.13 |
| Net working capital | 2,816 | 2,723 | 2,100 | 1,880 | 1,809 | 1,481 | 1,498 |
| Cash flow | |||||||
| Cash from operations | 809 | 227 | 773 | 730 | 545 | 1,485 | 540 |
| Cash from investing | (483) | (636) | (329) | (461) | (369) | (926) | (822) |
| Cash from financing | (318) | 404 | (445) | (261) | (217) | (534) | 166 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,868 | 1,719 | 1,642 | 1,796 | 1,494 | 1,571 | 1,406 | 1,580 |
| Revenue growth (YoY) | +25.0% | +9.4% | +16.8% | +13.7% | +1.3% | - | - | - |
| Other income | 14.04 | 25.88 | 10.73 | 11.49 | 7.79 | 13.21 | 15.46 | 28.93 |
| Total expenses | 1,522 | 1,469 | 1,413 | 1,493 | 1,280 | 1,400 | 1,226 | 1,321 |
| EBITDA | 346 | 249 | 229 | 303 | 214 | 171 | 180 | 259 |
| EBITDA margin | +18.5% | +14.5% | +14.0% | +16.9% | +14.3% | +10.9% | +12.8% | +16.4% |
| Depreciation | 82.54 | 82.31 | 79.67 | 75.64 | 73.37 | 68.60 | 69.69 | 70.12 |
| Interest | 21.41 | 19.42 | 21.65 | 22.81 | 22.64 | 23.71 | 21.79 | 18.28 |
| Profit before tax | 256 | 173 | 139 | 216 | 126 | 91.56 | 104 | 200 |
| Tax | 58.95 | (69.61) | 24.31 | 36.99 | 22.00 | 16.22 | 18.00 | 34.24 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 25 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,150 | 1,848 | 1,876 | 1,910 | 1,711 | 1,770 | 1,693 | 1,648 |
| Revenue growth (YoY) | +25.7% | +4.4% | +10.8% | +15.9% | +9.5% | - | - | - |
| Other income | 15.32 | 26.61 | 15.50 | 8.33 | 6.50 | 14.19 | 9.86 | 30.47 |
| EBITDA | 332 | 203 | 249 | 316 | 281 | 271 | 260 | 239 |
| EBITDA margin | +15.4% | +11.0% | +13.3% | +16.5% | +16.4% | +15.3% | +15.4% | +14.5% |
| Depreciation | 97.71 | 88.59 | 80.12 | 76.07 | 73.77 | 68.99 | 70.04 | 70.51 |
| Interest | 27.61 | 22.56 | 23.31 | 24.23 | 23.52 | 24.52 | 22.26 | 18.81 |
| Profit before tax | 222 | 119 | 162 | 224 | 190 | 192 | 178 | 180 |
| Tax | 49.50 | (82.91) | 29.55 | 40.01 | 36.48 | 35.31 | 40.08 | 27.28 |
| Net profit | 172 | 202 | 132 | 184 | 154 | 157 | 138 | 153 |
| EPS (₹) | 8.80 | 10.31 | 6.76 | 9.40 | 7.85 | 7.98 | 7.01 | 7.79 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 7,345 | 6,672 | 6,229 | 5,653 | 5,306 | 5,393 | 4,606 |
| Revenue growth | +10.1% | +7.1% | +10.2% | +6.5% | -1.6% | +17.1% | - |
| Other income | 54.66 | 56.30 | 28.30 | 2.74 | 55.74 | 87.29 | 4.94 |
| Total expenses | 6,293 | 5,664 | 5,296 | 4,975 | 4,432 | 3,913 | 3,426 |
| Employee cost | 1,732 | 1,562 | 1,446 | 1,169 | 1,133 | 1,051 | 906 |
| EBITDA | 1,051 | 1,008 | 932 | 677 | 874 | 1,480 | 1,179 |
| EBITDA margin | +14.3% | +15.1% | +15.0% | +12.0% | +16.5% | +27.5% | +25.6% |
| Depreciation | 319 | 279 | 273 | 275 | 287 | 183 | 157 |
| Interest | 93.63 | 78.77 | 56.19 | 50.17 | 17.73 | 16.02 | 27.16 |
| Profit before tax | 694 | 707 | 632 | 355 | 625 | 1,368 | 1,000 |
| Tax | 23.12 | 125 | 16.01 | 12.60 | 104 | 253 | 199 |
| Net profit | 731 | 563 | 613 | 346 | 518 | 1,141 | 862 |
| Net profit margin | +10.0% | +8.4% | +9.8% | +6.1% | +9.8% | +21.2% | +18.7% |
| EPS (₹) | 34.33 | 29.68 | 31.33 | 17.40 | 26.50 | 58.33 | 43.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 39.31 | 39.31 | 39.31 | 39.31 | 39.31 | 39.31 | 37.70 |
| Reserves & surplus | 5,636 | 5,152 | 4,779 | 4,331 | 5,198 | 5,028 | 3,182 |
| Shareholders' funds (net worth) | 5,675 | 5,191 | 4,818 | 4,370 | 5,238 | 5,067 | 3,219 |
| Minority interest | (5.83) | (1.42) | 0.00 | 0.00 | 0.00 | 0.00 | (28.96) |
| Secured loans | 219 | 118 | 100 | 165 | 0.00 | 0.02 | 0.04 |
| Unsecured loans | 1,210 | 1,140 | 413 | 557 | 717 | 584 | 1,747 |
| Total debt | 1,430 | 1,258 | 513 | 722 | 717 | 584 | 1,747 |
| Total liabilities | 7,432 | 6,571 | 5,441 | 5,199 | 6,050 | 5,736 | 5,086 |
| Assets | |||||||
| Gross block | 4,897 | 4,117 | 3,875 | 3,468 | 2,840 | 2,545 | 2,132 |
| Net block | 3,081 | 2,524 | 2,547 | 2,398 | 1,798 | 1,788 | 1,552 |
| Capital work in progress | 683 | 837 | 524 | 601 | 2,304 | 2,183 | 1,846 |
| Investments | 141 | 127 | 93.02 | 96.33 | 118 | 236 | 17.62 |
| Inventories | 2,511 | 2,288 | 1,644 | 1,475 | 1,610 | 1,486 | 1,188 |
| Sundry debtors | 1,466 | 1,400 | 1,025 | 1,046 | 807 | 349 | 865 |
| Cash & bank balances | 203 | 90.10 | 127 | 82.27 | 69.43 | 106 | 80.75 |
| Loans & advances | 363 | 310 | 284 | 306 | 375 | 524 | 330 |
| Total current assets | 4,543 | 4,088 | 3,079 | 2,910 | 2,861 | 2,465 | 2,463 |
| Total current liabilities | 1,331 | 1,202 | 1,005 | 984 | 1,072 | 969 | 891 |
| Net working capital | 3,212 | 2,886 | 2,074 | 1,926 | 1,789 | 1,496 | 1,572 |
| Total assets | 7,432 | 6,571 | 5,441 | 5,199 | 6,050 | 5,736 | 5,086 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 83.48 | 120 | 75.48 | 61.09 | 98.06 | 71.84 | 199 |
| Net cash from operating activities | 783 | 87.96 | 803 | 724 | 552 | 1,463 | 449 |
| Net cash from investing activities | (506) | (568) | (321) | (448) | (372) | (840) | (731) |
| Net cash from financing activities | (164) | 444 | (438) | (262) | (217) | (597) | 155 |
| Net change in cash | 113 | (36.73) | 44.73 | 14.39 | (36.97) | 26.22 | (127) |
| Closing cash | 203 | 90.10 | 127 | 82.27 | 69.43 | 106 | 80.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.1% | +7.1% | +10.2% | +6.5% | -1.6% | +17.1% | - |
| EBITDA growth | +4.3% | +8.1% | +37.6% | -22.5% | -41.0% | +25.5% | - |
| PBT growth | -1.9% | +11.9% | +78.2% | -43.3% | -54.3% | +36.8% | +33.4% |
| Net income growth | +29.8% | -8.1% | +77.2% | -33.3% | -54.6% | +32.4% | - |
| Revenue CAGR (3Y) | +9.1% | +7.9% | +4.9% | +7.1% | +10.5% | +19.9% | +14.0% |
| EBITDA CAGR (3Y) | +15.8% | +4.9% | -14.3% | -16.9% | +0.0% | +32.0% | +24.2% |
| Profitability & leverage | |||||||
| Net income margin | +9.1% | +8.7% | +9.9% | +6.1% | +9.8% | +20.7% | +17.4% |
| Return on capital employed | +11.2% | +13.1% | +12.9% | +7.2% | +10.9% | +25.5% | +22.8% |
| Return on net worth | +12.4% | +11.6% | +13.4% | +7.1% | +10.1% | +26.9% | +27.0% |
| Debt / equity | 0.25 | 0.18 | 0.13 | 0.15 | 0.13 | 0.28 | 0.48 |
| Long-term debt / equity | 0.02 | 0.01 | 0.01 | 0.01 | 0.03 | 0.14 | 0.23 |
| Interest cover | 12.77 | 10.80 | 8.52 | 12.48 | 3.02 | 1.24 | 2.66 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.63 | 1.67 | 1.70 | 1.79 | 1.97 | 2.31 | 2.52 |
| Inventory turnover | 3.06 | 3.39 | 3.99 | 3.66 | 3.43 | 4.03 | 4.27 |
| Debtors turnover | 5.13 | 5.50 | 6.01 | 6.10 | 9.18 | 8.89 | 6.80 |
| EPS (₹) | 34.33 | 29.68 | 31.33 | 17.40 | 26.50 | 58.33 | 43.97 |
| Dividend per share (₹) | 12.00 | 11.00 | 11.00 | 8.00 | 10.00 | 14.00 | 10.00 |
| Book value per share (₹) | 288.72 | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 | 170.79 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,868 | 1,719 | 1,642 | 1,796 | 1,494 | 1,571 | 1,406 | 1,580 |
| Revenue growth (YoY) | +25.0% | +9.4% | +16.8% | +13.7% | +1.3% | - | - | - |
| Other income | 14.04 | 25.88 | 10.73 | 11.49 | 7.79 | 13.21 | 15.46 | 28.93 |
| Total expenses | 1,522 | 1,469 | 1,413 | 1,493 | 1,280 | 1,400 | 1,226 | 1,321 |
| EBITDA | 346 | 249 | 229 | 303 | 214 | 171 | 180 | 259 |
| EBITDA margin | +18.5% | +14.5% | +14.0% | +16.9% | +14.3% | +10.9% | +12.8% | +16.4% |
| Depreciation | 82.54 | 82.31 | 79.67 | 75.64 | 73.37 | 68.60 | 69.69 | 70.12 |
| Interest | 21.41 | 19.42 | 21.65 | 22.81 | 22.64 | 23.71 | 21.79 | 18.28 |
| Profit before tax | 256 | 173 | 139 | 216 | 126 | 91.56 | 104 | 200 |
| Tax | 58.95 | (69.61) | 24.31 | 36.99 | 22.00 | 16.22 | 18.00 | 34.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 6,651 | 6,033 | 5,874 | 5,149 | 5,035 | 5,067 | 4,133 |
| Revenue growth | +10.3% | +2.7% | +14.1% | +2.3% | -0.6% | +22.6% | - |
| Other income | 55.90 | 60.75 | 505 | 3.55 | 51.14 | 83.90 | 135 |
| Total expenses | 5,656 | 5,131 | 5,349 | 4,485 | 4,127 | 3,618 | 2,940 |
| Employee cost | 1,613 | 1,467 | 1,336 | 1,095 | 1,062 | 976 | 806 |
| EBITDA | 996 | 901 | 525 | 664 | 909 | 1,449 | 1,193 |
| EBITDA margin | +15.0% | +14.9% | +8.9% | +12.9% | +18.1% | +28.6% | +28.9% |
| Depreciation | 311 | 277 | 271 | 273 | 285 | 183 | 136 |
| Interest | 86.51 | 76.47 | 54.47 | 49.00 | 17.02 | 12.98 | 25.19 |
| Profit before tax | 654 | 609 | 704 | 346 | 658 | 1,338 | 1,167 |
| Tax | 13.69 | 105 | 37.75 | (0.80) | 114 | 241 | 197 |
| Net profit | 697 | 483 | 665 | 347 | 541 | 1,091 | 976 |
| Net profit margin | +10.5% | +8.0% | +11.3% | +6.7% | +10.7% | +21.5% | +23.6% |
| EPS (₹) | 32.58 | 25.60 | 33.91 | 17.64 | 27.65 | 55.79 | 51.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 39.31 | 39.31 | 39.31 | 39.31 | 39.31 | 39.31 | 37.70 |
| Reserves & surplus | 5,576 | 5,155 | 4,870 | 4,375 | 5,251 | 5,062 | 3,308 |
| Shareholders' funds (net worth) | 5,615 | 5,195 | 4,909 | 4,414 | 5,290 | 5,102 | 3,346 |
| Secured loans | 219 | 102 | 100 | 165 | 0.00 | 0.02 | 0.04 |
| Unsecured loans | 979 | 1,092 | 392 | 545 | 706 | 584 | 1,687 |
| Total debt | 1,198 | 1,194 | 492 | 710 | 706 | 584 | 1,687 |
| Total liabilities | 6,966 | 6,513 | 5,510 | 5,230 | 6,092 | 5,771 | 5,180 |
| Assets | |||||||
| Gross block | 4,629 | 4,101 | 3,859 | 3,606 | 2,733 | 2,452 | 1,762 |
| Net block | 2,828 | 2,513 | 2,536 | 2,377 | 1,771 | 1,774 | 1,276 |
| Capital work in progress | 683 | 837 | 524 | 601 | 2,304 | 2,183 | 1,570 |
| Investments | 271 | 260 | 227 | 229 | 219 | 343 | 833 |
| Inventories | 2,048 | 1,976 | 1,353 | 1,275 | 1,397 | 1,342 | 1,073 |
| Sundry debtors | 1,604 | 1,481 | 1,340 | 1,201 | 988 | 422 | 784 |
| Cash & bank balances | 28.74 | 20.85 | 26.49 | 28.46 | 21.90 | 61.44 | 37.13 |
| Loans & advances | 320 | 288 | 269 | 275 | 337 | 482 | 257 |
| Total current assets | 4,001 | 3,766 | 2,989 | 2,780 | 2,744 | 2,308 | 2,151 |
| Total current liabilities | 1,185 | 1,043 | 888 | 900 | 935 | 826 | 653 |
| Net working capital | 2,816 | 2,723 | 2,100 | 1,880 | 1,809 | 1,481 | 1,498 |
| Total assets | 6,966 | 6,513 | 5,510 | 5,230 | 6,092 | 5,771 | 5,180 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 14.23 | 20.13 | 21.67 | 13.56 | 53.66 | 28.22 | 144 |
| Net cash from operating activities | 809 | 227 | 773 | 730 | 545 | 1,485 | 540 |
| Net cash from investing activities | (483) | (636) | (329) | (461) | (369) | (926) | (822) |
| Net cash from financing activities | (318) | 404 | (445) | (261) | (217) | (534) | 166 |
| Net change in cash | 8.44 | (5.90) | (1.54) | 8.11 | (40.10) | 25.22 | (116) |
| Closing cash | 28.74 | 20.85 | 26.49 | 28.46 | 21.90 | 61.44 | 37.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.3% | +2.7% | +14.1% | +2.3% | -0.6% | +22.6% | - |
| EBITDA growth | +10.5% | +71.7% | -21.0% | -26.9% | -37.3% | +21.5% | - |
| PBT growth | +7.5% | -13.6% | +103.6% | -47.4% | -50.8% | +14.7% | +52.6% |
| Net income growth | +44.3% | -27.4% | +92.0% | -35.9% | -50.5% | +11.8% | - |
| Revenue CAGR (3Y) | +8.9% | +6.2% | +5.1% | +7.6% | +11.2% | +19.8% | +11.4% |
| EBITDA CAGR (3Y) | +14.4% | -0.3% | -28.7% | -17.7% | +1.1% | +31.8% | +23.5% |
| Profitability & leverage | |||||||
| Net income margin | +9.6% | +8.3% | +11.4% | +6.7% | +10.8% | +21.6% | +23.5% |
| Return on capital employed | +12.0% | +11.4% | +14.1% | +7.0% | +11.4% | +24.7% | +26.5% |
| Return on net worth | +12.9% | +10.0% | +14.3% | +7.2% | +10.5% | +26.0% | +32.0% |
| Debt / equity | 0.22 | 0.17 | 0.13 | 0.15 | 0.12 | 0.27 | 0.45 |
| Long-term debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.14 | 0.23 |
| Interest cover | 12.63 | 12.25 | 21.46 | 12.52 | 2.73 | 1.02 | 2.38 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.52 | 1.52 | 1.57 | 1.62 | 1.94 | 2.40 | 2.59 |
| Inventory turnover | 3.31 | 3.62 | 4.47 | 3.85 | 3.68 | 4.20 | 4.21 |
| Debtors turnover | 4.31 | 4.28 | 4.62 | 4.70 | 7.14 | 8.40 | 6.24 |
| EPS (₹) | 32.58 | 25.60 | 33.91 | 17.64 | 27.65 | 55.79 | 51.43 |
| Dividend per share (₹) | 12.00 | 11.00 | 11.00 | 8.00 | 10.00 | 14.00 | 10.00 |
| Book value per share (₹) | 285.69 | 264.30 | 249.75 | 224.59 | 269.16 | 259.57 | 177.51 |
To see the full year-wise statements and ratios of Alembic Pharmaceuticals Limited, buy the company report.
Board of directors of Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals has 9 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chirayu Ramanbhai Amin | Whole-Time Director | 16 Jun 2010 | 16 Years 4 Months | Current |
| Ashok Kumar Barat | Director | 10 Feb 2022 | 4 Years 8 Months | Current |
| Rajkumar Shreeram Baheti | Whole-Time Director | 16 Jun 2010 | 16 Years 4 Months | Current |
| Pranav Chirayu Amin Also directs: Viramya Packlight LLP, Elecon Engineering Company Limited, Max Healthcare Institute Limited and 5 more | Managing Director | 31 Mar 2011 | 15 Years 6 Months | Current |
| Shaunak Chirayu Amin | Managing Director | 02 May 2013 | 13 Years 5 Months | Current |
| Geeta Amit Goradia Also directs: Jewel Consumer Care Private Limited | Director | 03 Feb 2025 | 1 Years 8 Months | Current |
Showing 6 of 9 current directors. View all directors
Peer comparison
Alembic Pharmaceuticals Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Limited | ₹7,963.26 Cr (FY 2025) | 19.0% | Pune, Maharashtra, India | |||
| Mylan Laboratories Limited | ₹7,503.56 Cr (FY 2025) | -23.0% | Hyderabad, Telangana, India | |||
| Alembic Pharmaceuticals Limitedthis company | ₹7,344.9 Cr (FY 2026) | ₹730.89 Cr | 10% | 10.1% | 15,822 | Vadodara, Gujarat, India |
| Apitoria Pharma Private Limited | ₹6,811.62 Cr (FY 2025) | 20.0% | Hyderabad, Telangana, India | |||
| MSN Laboratories Private Limited | ₹6,761.18 Cr (FY 2024) | 27.0% | Hyderabad, Telangana, India | |||
| Gland Pharma Ltd | ₹5,830.11 Cr (FY 2025) | 0.0% | Hyderabad, Telangana, India | |||
| Laurus Labs Limited | ₹5,613.89 Cr (FY 2025) | 11.0% | Anakapalle, Andhra Pradesh, India | |||
| Aristo Pharmaceuticals Private Limited | ₹5,363.3 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Usv Private Limited | ₹5,202.13 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Natco Pharma Limited | ₹4,784 Cr (FY 2025) | 16.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Alembic Pharmaceuticals Limited, buy the company report.
Auditor
Alembic Pharmaceuticals Limited is audited by K C MEHTA & CO LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K C MEHTA & CO LLP | FY 2023 | 106237W/W100829 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 69.90%, foreign institutional investors hold 4.20%, domestic institutional investors hold 15.90% and retail and other public shareholders hold 10.00%.
Sep 2026
QUARTER
69.90% Promoters
15.90% DII (Domestic Institutional)
4.20% FII (Foreign Institutional)
10.00% Retail & Others
Promoter holding - history
Now 69.90% · Sep 2026High 69.90% · Sep 2026Low 69.70% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 69.90% | 69.70% | 69.70% | 69.70% |
| Public | 30.10% | 30.30% | 30.30% | 30.30% |
Charges & borrowings
Open charges
₹600 Cr
Satisfied charges
₹219.36 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Jun 2011 | 10296745 | Others | ₹600 Cr | Open | |
| 19 Nov 2021 | 100510305 | Hdfc Bank Limited | ₹5 Cr | Satisfied | |
| 26 Jul 2021 | 100469987 | Yes Bank Limited | ₹10 Cr | Satisfied | |
| 08 May 2014 | 10534523 | Bank of Baroda | ₹1.36 Cr | Satisfied | |
| 02 Dec 2011 | 10323112 | Dbs Bank Limited | ₹78 Cr | Satisfied |
To see the full charge records of Alembic Pharmaceuticals Limited, buy the company report.
Total charge records: 8 View all charges
Deals & funding
Alembic Pharmaceuticals Limited has 10 deals on record (8 market trades, 1 qip, 1 acquisition); the latest was in October 2022.
Total deals
10
Market trades
8
QIP
1
Acquisition
1
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2020 | QIP | ₹750 Cr | Investors: Tata Mutual Fund, HDFC Life Insurance Company Limited , IDFC Mutual Fund |
| Aug 2017 | Acquisition | Undisclosed | Buyer: Scott Edil Pharmacia Limited Seller: Alembic Pharmaceuticals Limited |
| Mar 2017 | Market trade | ₹84.28 Cr | Buyer: Shreno Limited, Sierra Investments Limited Seller: Viramya Packlight LLP |
| Mar 2017 | Market trade | ₹119 Cr | Buyer: Shreno Limited Seller: Viramya Packlight LLP |
| Mar 2017 | Market trade | ₹95.52 Cr | Buyer: Shreno Limited Seller: Viramya Packlight LLP |
To see the full deal history of Alembic Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Alembic Pharmaceuticals Limited has 358 court cases on record: 305 filed by Alembic Pharmaceuticals, 53 filed against it. 97 cases are pending and 261 are disposed.
Total cases
358
Filed by the company
305
Filed against the company
53
Pending
97
Disposed
261
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 279 | 33 | 73 |
| High courts | 73 | 18 | 23 |
| Supreme Court | 6 | 2 | 1 |
Cases on record (5 of 358)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Gujarat | Special civil application | Filed by the company against Madhya Gujarat Vij Company Limited and 1 other | Pending |
| High Court of Delhi | Court case (C.O. (COMM.IPD-TM)) | Filed against the company by 1. Cedar Properties and Trading LLP | Pending |
| District court, Vadodara, Gujarat | Commercial matter | Filed by the company against Bionexy Pharmaceuticals Pvt.Ltd. | Disposed |
| High Court of Gujarat | Special civil application | Filed by the company against Madhya Gujarat Vij Company Limited and 1 other | Disposed |
| High Court of Delhi | Commercial suit | Filed against the company by Mankind Pharma Limited | Disposed |
To see the full case history of Alembic Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Alembic Pharmaceuticals Limited was last rated by Care on 11 Jun 2026.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 11 Jun 2026 |
To see the full credit ratings and regulatory alerts of Alembic Pharmaceuticals Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Alembic Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Alembic Pharmaceuticals has 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Associated companies
Employees & EPFO
Alembic Pharmaceuticals Limited has a workforce of 15,822 employees on its EPFO records as of Feb 11, 2025, across 1 active EPFO establishment.
Employee count
15,822
Active EPFO establishments
1
Employee growth
3.66%
GST
Alembic Pharmaceuticals has 28 GST registrations: 23 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
28
Active
23
Cancelled / inactive
5
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAICA5591M1Z9 | Gujarat | Active | 01 Jul 2017 |
| 24AAICA5591M2Z8 | Gujarat | Active | 23 Aug 2017 |
| 03AAICA5591M1ZD | Punjab | Active | 01 Jul 2017 |
| 06AAICA5591M1Z7 | Haryana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Alembic Pharmaceuticals Limited, buy the company report.
Recent activity
Alembic Pharmaceuticals Limited has 22 board changes on record since 2010: 16 appointments and 6 cessations. The latest: Sujit Jaysukh Bhayani was appointed as Additional Director on 18 Jun 2026.
Appointed
Sujit Jaysukh Bhayani was appointed as Additional Director.
Filing
Alembic Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
AGM
Alembic Pharmaceuticals Limited last Annual general meeting of members was held on 05 Aug 2025 as per latest MCA records.
Ceased
Archana Niranjan Hingorani ceased to be Director.
Appointed
Geeta Amit Goradia was appointed as Director.
Ceased
Krishnapuram Gopalakrishnan Ramanathan ceased to be Director.
Ceased
Paresh Manilal Saraiya ceased to be Director.
Ceased
Pranav Natverlal Parikh ceased to be Director.
Appointed
Manish Santoshkumar Kejriwal was appointed as Director.
Charges
A charge registered on 26 Jul 2021 via Charge ID 100469987 with Yes Bank Limited was fully satisfied on 13 Jun 2023.
Appointed
Jai Shishir Diwanji was appointed as Director.
Appointed
Manisha Saraf was appointed as Company Secretary.
29 earlier events are in the company report.
News
Alembic Pharma: Gets USFDA Approval For Ciprofloxacin And Dexamethasone Otic Suspension, Which Sells USD 110M Yearly.
Alembic Pharmaceuticals: Steps Down Its Dubai-Based Subsidiary Alvesta Pharmaceuticals
Alembic Pharmaceuticals: Co Receives Usfda Final Approval For Ciprofloxacin And Dexamethasone Otic Suspension Usp, 0.3% / 0.1%.
Alembic Pharmaceuticals: Plans Meeting With Analysts And Investors On September 23 At 10 AM
Alembic Pharma: Company Usfda Issues Eir, Closes Inspection At Vadodara Bioequivalence Facility
Frequently asked questions
Alembic Pharmaceuticals is an active public limited company based in Vadodara, Gujarat, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 16 June 2010 (16+ years old) and is registered under CIN L24230GJ2010PLC061123. Listed on BSE: 533573 and NSE: APLLTD.
Alembic Pharmaceuticals reported revenue of ₹7,344.9 Cr for FY 2025-26 (up 10.1% YoY) based on consolidated financials.
Alembic Pharmaceuticals has 9 current directors:
- Pranav Chirayu Amin - Managing Director
- Shaunak Chirayu Amin - Managing Director
- Chirayu Ramanbhai Amin - Whole-Time Director
- Rajkumar Shreeram Baheti - Whole-Time Director
- Ashok Kumar Barat - Director
- Geeta Amit Goradia - Director
- Manish Santoshkumar Kejriwal - Director
- Jai Shishir Diwanji - Director
- Sujit Jaysukh Bhayani - Additional Director
The latest financial statements of Alembic Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 05 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Alembic Pharmaceuticals is 24AAICA5591M1Z9, registered in Gujarat. The company has 28 GST registrations in all, of which 23 are active and 5 are cancelled or inactive. Other active GSTINs include 24AAICA5591M2Z8 (Gujarat), 03AAICA5591M1ZD (Punjab), 06AAICA5591M1Z7 (Haryana).
The CIN (Corporate Identification Number) of Alembic Pharmaceuticals is L24230GJ2010PLC061123. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Alembic Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 533573) and NSE (symbol: APLLTD).
Alembic Pharmaceuticals has 358 court cases on record: 305 filed by the company and 53 filed against it. 97 are pending. Most are in the district courts.
Alembic Pharmaceuticals was incorporated on 16 June 2010, making it 16+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Alembic Pharmaceuticals has 10 deals on record (8 market trades, 1 qip, 1 acquisition); the latest was in October 2022.
The peers of Alembic Pharmaceuticals by revenue are Emcure Pharmaceuticals Limited, Mylan Laboratories Limited, Apitoria Pharma Private Limited, MSN Laboratories Private Limited, Gland Pharma Ltd and 4 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).